Barclays PLC Acquires 154,436 Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

Barclays PLC boosted its holdings in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) by 391.6% in the third quarter, according to its most recent filing with the SEC. The firm owned 193,873 shares of the biopharmaceutical company’s stock after acquiring an additional 154,436 shares during the period. Barclays PLC’s holdings in Lexicon Pharmaceuticals were worth $304,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Geode Capital Management LLC raised its position in shares of Lexicon Pharmaceuticals by 8.4% in the 3rd quarter. Geode Capital Management LLC now owns 3,523,971 shares of the biopharmaceutical company’s stock valued at $5,534,000 after acquiring an additional 273,436 shares during the period. XTX Topco Ltd bought a new stake in Lexicon Pharmaceuticals in the third quarter valued at approximately $126,000. State Street Corp raised its holdings in Lexicon Pharmaceuticals by 6.8% in the third quarter. State Street Corp now owns 2,471,215 shares of the biopharmaceutical company’s stock worth $3,880,000 after purchasing an additional 157,738 shares during the period. Atom Investors LP bought a new position in shares of Lexicon Pharmaceuticals during the third quarter worth $122,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new position in shares of Lexicon Pharmaceuticals in the 3rd quarter valued at $189,000. Institutional investors own 74.70% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently commented on LXRX. Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research note on Monday, December 23rd. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Lexicon Pharmaceuticals in a research report on Wednesday, November 13th. Finally, Leerink Partners set a $6.00 price objective on Lexicon Pharmaceuticals and gave the company an “outperform” rating in a report on Friday, October 18th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $6.00.

Lexicon Pharmaceuticals Trading Down 3.3 %

NASDAQ:LXRX opened at $0.69 on Tuesday. The company has a quick ratio of 7.43, a current ratio of 7.45 and a debt-to-equity ratio of 0.56. Lexicon Pharmaceuticals, Inc. has a twelve month low of $0.62 and a twelve month high of $3.73. The company has a market cap of $169.91 million, a P/E ratio of -0.92 and a beta of 1.06. The business has a 50 day moving average price of $0.81 and a two-hundred day moving average price of $1.42.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.01). Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. The company had revenue of $1.75 million during the quarter, compared to the consensus estimate of $3.14 million. During the same quarter in the previous year, the business earned ($0.21) EPS. As a group, analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.66 EPS for the current fiscal year.

Lexicon Pharmaceuticals Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.